Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 2/20 | 0.39 |
| ▸ | PRKACA | P17612 | 5/20 | 0.38 |
| ▸ | RPS6KB1 | P23443 | 5/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 4/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | EP300 | Q09472 | 1/20 | 0.32 |
| ▸ | USP14 | P54578 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2031673 | 1.00 | MET (0.39) | METPRKACARPS6KB1EGFRCNR2 | |
| SCHEMBL2031496 | 0.89 | KDM4E (0.45) | PRKACARPS6KB1EGFRCNR2GSK3B | |
| SCHEMBL2032453 | 0.79 | RPS6KB1 (0.47) | RPS6KB1ALDH1A1MAPT | |
| SCHEMBL19892305 | 0.72 | TEC (0.41) | — | |
| SCHEMBL2031499 | 0.72 | ALDH1A1 (0.42) | PRKACARPS6KB1GSK3BROCK1KDM4E | |
| SCHEMBL2361197 | 0.69 | KDM4E (0.49) | PRKACARPS6KB1CNR2GSK3BROCK1 | |
| SCHEMBL15205485 | 0.68 | CNR2 (0.34) | METCNR2EP300RORC | |
| SCHEMBL15205484 | 0.68 | CNR2 (0.34) | METCNR2EP300RORC | |
| SCHEMBL2033562 | 0.67 | PRKACA (0.53) | PRKACARPS6KB1EGFRCNR2GSK3B | |
| SCHEMBL2033557 | 0.67 | PRKACA (0.53) | PRKACARPS6KB1EGFRCNR2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293923-B2 | Indazole derivatives as modulators of interleukin-1 receptor-associated kinase | BIOGEN IDEC MA INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20110152260-A1 | Indazole derivatives as modulators of interleukin-1 receptor-associated kinase | BIOGEN IDEC MA INC. (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152260-A1 | Indazole derivatives as modulators of interleukin-1 receptor-associated kinase | IRAK1, IRAK2, IRAK3 | MET 994/4885PRKACA 478/4885RPS6KB1 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.